Advertisement
Screener

SAB BIOTHERAPEUTICS, INC. (SABS) Equity Securities, FV-NI, Unrealized Gain

1.5 / 5 stars · 13/43 Roast Me

SAB BIOTHERAPEUTICS, INC. Equity Securities, FV-NI, Unrealized Gain

SAB BIOTHERAPEUTICS, INC. (SABS) reported Equity Securities, FV-NI, Unrealized Gain of $53.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.

Financial Statements › Income Statement › Other Income

us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2025-05-09

  • SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-12-31 was $0.00.
  • SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-09-30 was $38.00K.
  • SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-06-30 was $7.00K.
  • SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-03-31 was $7.00K.
  • SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain for fiscal 2024 was $53.00K.
Period endEquity Securities, FV-NI, Unrealized Gain 3 monthEquity Securities, FV-NI, Unrealized Gain 6 monthEquity Securities, FV-NI, Unrealized Gain 9 monthEquity Securities, FV-NI, Unrealized Gain 12 month
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$38.00K
derived: sum of 2 quarters · filed 2025-03-31
$45.00K
derived: sum of 3 quarters · filed 2025-03-31
$53.00K
10-K · filed 2025-03-31
2024-09-30$38.00K
10-Q · filed 2024-11-06
$45.00K
derived: sum of 2 quarters · filed 2024-11-06
$53.00K
10-Q · filed 2024-11-06
2024-06-30$7.00K
10-Q · filed 2024-08-08
$15.00K
10-Q · filed 2024-08-08
2024-03-31$7.00K
10-Q · filed 2025-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Ocugen, Inc. (OCGN)United States$0.343B-6.34
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05